The combination of duvelisib and romidepsin (dr) is highly active against relapsed/refractory peripheral t‐cell lymphoma with low rates of transaminitis: final results S. M. Horwitz, A. J. Moskowitz, N. Mehta‐Shah, E. D. Jacobsen, M. S. Khodadoust,N. Ganesan,E. Drill,H. Hancock,T. Davey, P. Myskowski, C. Maccaro, W. Blouin, J. Schwieterman, E. Cathcart, S. Fang,L. Perez, S. Ryu,N. Galasso, D. Straus, D. C. Fisher, A. Kumar, A. Noy,L. Falchi, A. Dogan, Y. H. Kim,D. WeinstockHematological Oncology（2021）引用 9|浏览1暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
